Search Results

CARAG AG, a privately-held Swiss medical device development company, announced receiving U.S. Food and Drug Administration Investigational Device Exemption approval for its Carag Bioresorbable Septal Occluder.

CARAG AG announced the successful implantation of the first-ever transcatheter septal occluder with bioresorbable, metal-free framework, as part of a new international post-market registry.

Mainz Biomed N.V. announces that its presentation at the 35th Annual Piper Sandler Healthcare Conference, to be delivered by Chief Executive Officer, Guido Baechler and Bill Caragol, Chief Financial Officer, will be available to view live and post event via webcast by registering at the following link.

Mainz Biomed N.V. announces that Guido Baechler, Chief Executive Officer, and Bill Caragol, Chief Financial Officer, will present at the 35th Annual Piper Sandler Healthcare Conference taking place on the 28-30 November, 2023 in New York, NY, USA.

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Bill Caragol, Chief Financial Officer, will attend the JonesTrading 2023 Healthcare Summit which will take place October 9-11, 2023 in Miami Beach, Florida.

Mainz Biomed NV announced that Bill Caragol, the Company’s CFO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 22-23, 2023.

Mainz Biomed N.V. announced that its Chief Financial Officer Bill Caragol will appear on ClearThink IR Virtual Live on Wednesday, March 1, 2023 at 12 noon ET.

Company prepares for U.S. IDE clinical trial of its novel metal-free frame designed to reduce complications and preserve long-term treatment options

Mainz Biomed N.V. announced that Bill Caragol, Chief Financial Officer, will present at the H.C. Wainwright Annual Global Investment Conference taking place from September 12-14, 2022.